209 related articles for article (PubMed ID: 31287573)
1. Intranasal bevacizumab injections improve quality of life in HHT patients.
Steineger J; Geirdal AØ; Osnes T; Heimdal KR; Dheyauldeen S
Laryngoscope; 2020 May; 130(5):E284-E288. PubMed ID: 31287573
[TBL] [Abstract][Full Text] [Related]
2. Long-term experience with intranasal bevacizumab therapy.
Steineger J; Osnes T; Heimdal K; Dheyauldeen S
Laryngoscope; 2018 Oct; 128(10):2237-2244. PubMed ID: 29469958
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
[TBL] [Abstract][Full Text] [Related]
4. Injection of bevacizumab and cyanoacrylate glue for hereditary hemorrhagic telangiectasia.
Khoueir N; Borsik M; Camous D; Herman P; Verillaud B
Laryngoscope; 2019 Oct; 129(10):2210-2215. PubMed ID: 31566760
[TBL] [Abstract][Full Text] [Related]
5. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
[TBL] [Abstract][Full Text] [Related]
6. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review.
Stokes P; Rimmer J
Rhinology; 2018 Mar; 56(1):3-10. PubMed ID: 29166422
[TBL] [Abstract][Full Text] [Related]
7. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial.
Riss D; Burian M; Wolf A; Kranebitter V; Kaider A; Arnoldner C
Head Neck; 2015 Jun; 37(6):783-7. PubMed ID: 24595923
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial.
Peterson AM; Lee JJ; Kallogjeri D; Schneider JS; Chakinala MM; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1006-1014. PubMed ID: 32940653
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
Karnezis TT; Davidson TM
Laryngoscope; 2011 Mar; 121(3):636-8. PubMed ID: 21344445
[TBL] [Abstract][Full Text] [Related]
10. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
Chen S; Karnezis T; Davidson TM
Laryngoscope; 2011 Mar; 121(3):644-6. PubMed ID: 21344447
[TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report.
Steineger J; Merckoll E; Slåstad JM; Eriksen EF; Heimdal K; Dheyauldeen S
Laryngoscope; 2018 Mar; 128(3):593-596. PubMed ID: 28671294
[TBL] [Abstract][Full Text] [Related]
12. Hereditary hemorrhagic telangiectasia/avastin.
Davidson TM; Olitsky SE; Wei JL
Laryngoscope; 2010 Feb; 120(2):432-5. PubMed ID: 19998344
[TBL] [Abstract][Full Text] [Related]
13. Medical Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Meta-analysis.
Hsu YP; Hsu CW; Bai CH; Cheng SW; Chen C
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):22-35. PubMed ID: 30200816
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
[TBL] [Abstract][Full Text] [Related]
15. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
[TBL] [Abstract][Full Text] [Related]
16. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.
Rohrmeier C; Sachs HG; Kuehnel TS
Eur Arch Otorhinolaryngol; 2012 Feb; 269(2):531-6. PubMed ID: 21805356
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy.
Karnezis TT; Davidson TM
Laryngoscope; 2012 Mar; 122(3):495-7. PubMed ID: 22147664
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab as Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Literature Review.
Kini SD; Yiu DW; Weisberg RA; Davila JF; Chelius DC
Ann Otol Rhinol Laryngol; 2019 May; 128(5):467-471. PubMed ID: 30693788
[TBL] [Abstract][Full Text] [Related]
19. Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding.
Iyer VN; Apala DR; Pannu BS; Kotecha A; Brinjikji W; Leise MD; Kamath PS; Misra S; Begna KH; Cartin-Ceba R; DuBrock HM; Krowka MJ; O'Brien EK; Pruthi RK; Schroeder DR; Swanson KL
Mayo Clin Proc; 2018 Feb; 93(2):155-166. PubMed ID: 29395350
[TBL] [Abstract][Full Text] [Related]
20. Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
Azzopardi N; Dupuis-Girod S; Ternant D; Fargeton AE; Ginon I; Faure F; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Leguy-Seguin V; Rivière S; Corre R; Bailly S; Paintaud G
MAbs; 2015; 7(3):630-7. PubMed ID: 25751241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
